Neurodegeneration – News and Features

Researchers have illuminated the role of chaperone proteins in protein folding in unprecedented detail using cryo-electron tomography.

Researchers found that an episode of shingles is linked to a 20% increased risk of subjective cognitive decline, an early symptom of dementia. The study highlights the potential role of the shingles vaccine in reducing the burden of cognitive decline.

A University of Gothenburg study highlights the potential of the Ronnie Gardiner Method, a music-based movement therapy, to aid stroke rehabilitation and brain disorder recovery.

A new study examining older Black Americans’ perceptions of Alzheimer’s disease has found a lack of awareness of the devastating condition. The authors propose strategies for supporting brain health in this population.

Carnegie Mellon researchers discovered that the motor cortex plays a leading role in controlling movement, guiding striatal activity for both skilled and unskilled actions. By removing the motor cortex in mice, they observed impaired movement.

Learn from James Hallam, vice president of the Research, Development and Advanced Testing Business segment at Waters Corporation, about how technological advancements in mass spectrometry are powering new discoveries in omics research.

A study found that lecanemab effectively targets amyloid plaques in brain tissue of people with Down syndrome, who are prone to early Alzheimer's. While promising, the drug also binds to brain blood vessels, raising safety concerns.

Adaptive deep brain stimulation could provide round-the-clock personalized care for people with Parkinson’s disease, treating movement problems during the day and insomnia at night.

Researchers have developed a method to isolate and analyze microglia phagosomes in a rapid, gentle, and unbiased fashion. They also share new insights regarding synaptic pruning and generation of NAD+, a broadly used molecule in the brain, by microglia.

With new medications on the market or in the works for Alzheimer’s disease and other kinds of dementia, a study suggests that getting the diagnosis needed to access these new treatments may depend on where you live.